Solriamfetol Effective for Managing ADHD in Adults
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 17, 2023 -- Solriamfetol seems to be effective for management of attention-deficit/hyperactivity disorder (ADHD) in adults, according to a study published online Oct. 9 in the Journal of Clinical Psychiatry.
Craig B. H. Surman, M.D., from Massachusetts General Hospital in Boston, and colleagues performed a remotely conducted, randomized, double-blind, six-week dose-optimization trial of 75 or 150 mg of solriamfetol in 60 adults with ADHD.
The researchers found that solriamfetol was well tolerated with no significant effect on mean heart rate, systolic blood pressure, or diastolic blood pressure. No significant treatment effect on the occurrence of adverse events was seen. Individuals on solriamfetol treatment experienced adverse events in several categories at a rate of at least 10 percentage points higher than individuals on placebo. By study end point, a significantly greater proportion of individuals in the treatment group met the a priori-defined treatment response (Clinical Global Impressions scale score indicating much or very much improved and Adult ADHD Investigator Symptom Rating Scale [AISRS] score reduced ≥25 percent: 45 versus 6.9 percent). Greater improvement in total AISRS scores by weeks 3 through 6 was also seen for those treated with solriamfetol. A 0.5 standard deviation improvement in T-score on the Behavior Rating Inventory of Executive Function-Adult Form Global Executive Composite occurred in significantly more solriamfetol-treated adults. In addition, they had greater mean change in the Global Assessment of Functioning score.
"Our findings offer hope of a new method of supporting the daily challenges that individuals with ADHD face," Surman said in a statement.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Pharmacological Treatment of ADHD May Cut Some Forms of Criminality
WEDNESDAY, May 29, 2024 -- Pharmacological treatment may reduce some types of criminality among adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD)...
One in Nine U.S. Children Have Ever Been Diagnosed With ADHD
THURSDAY, May 23, 2024 -- Diagnoses of attention-deficit/hyperactivity disorder (ADHD) in U.S. children continue to increase, with approximately one in nine having ever received a...
Prenatal Opioid Exposure Not Tied to Neuropsychiatric Disorders in Offspring
THURSDAY, April 25, 2024 -- Prenatal opioid exposure seems not to be associated with a meaningful increase in the risk for neuropsychiatric disorders in offspring, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.